On December 11, 2019, the Children’s Tumor Foundation hosted a free webinar to talk about the progress and promise in NF2 research.
At the core of the Children’s Tumor Foundation’s commitment to NF2 research is the NF2 Accelerator Initiative, which is hyper-focused on bringing NF2 treatments to the clinic, and patients, through the following priority areas:
-Expanding the NF2 clinical drug pipeline
-Improving NF2 drug selection
-Growing gene therapy efforts for NF2.
Presenters included:
-Annette Bakker, PhD, Children’s Tumor Foundation
-Salvo LaRosa, PhD, Children’s Tumor Foundation
-Scott Plotkin, MD, PhD, Massachusetts General Hospital
-Michael Wootten, MBA, NF Therapeutics
Click the image below to view the webinar and the Q&A; to enable closed-captioning, click CC in the lower right corner.
To independently view the presentation itself, please click here.
During this webinar, Annette Bakker referred to CTF’s Synodos for NF2 initiative that identified Brigatinib as a promising candidate for NF2, and a presentation from February 2019 discussing the status and progress of the clinical trial presented by Dr. Jaishri Blakely; click here to view this presentation (jump to 34:50).
To support the NF2 Accelerator Initiative, please visit ctf.org/endnf2. If you have additional questions, please email info@ctf.org and put NF2 Webinar in the subject line.
